$15.2 Billion Clinical Chemistry Analyzers Markets, 2025 - Fully-Automated Analyzers, PoC Analyzers, Reagents, Basic Metabolic, Liver, Renal, Lipid, Thyroid Function - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Clinical Chemistry Analyzers Market by Product (Fully-Automated Analyzers, PoC Analyzers, Reagents), Test Type (Basic Metabolic, Liver, Renal, Lipid, Thyroid Function), End User (Hospitals, Clinics, Laboratories, Research) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Clinical Chemistry Analyzers Market Size is Projected to Reach USD 15.2 Billion by 2026 from USD 12.3 Billion in 2021, at a CAGR of 4.3%

Market growth is driven by factors such as the rising geriatric population and the increasing prevalence of chronic & lifestyle diseases, growing adoption of Point-of-Care testing devices and rising demand for laboratory automation. On the other hand, high capital investment, shortage of clinical laboratory technicians, and the availability of refurbished products is expected to limit market growth to a certain extent in the coming years.

The reagents accounted for the highest growth rate in the clinical chemistry analyzers market, by product, during the forecast period

The clinical chemistry analyzers market is segmented into analyzers, reagents and other products. The reagents segment accounted for the highest growth rate in the clinical chemistry analyzers market in 2020. The requirement reagents in large numbers compared to analyzers is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of reagents compared to analyzers.

Lipid profile tests segment accounted for the highest CAGR

Based on the test type, the clinical chemistry analyzers market is segmented basic metabolic panels, electrolyte panels, liver panels, lipid profiles, renal profiles, thyroid function panels, and specialty chemical tests. In 2020, the lipid profile tests segment accounted for the highest growth rate. Rapid growth in obesity rates and the increasing incidence of obesity-related diseases are the major factors driving this segment's growth.

Hospitals and clinics segment accounted for the highest CAGR

Based on end-users, the clinical chemistry analyzers market is segmented into hospitals and clinics, diagnostic laboratories, research laboratories & institutes, and other end users. In 2020, the hospitals and clinics segment accounted for the highest growth rate. This can be attributed to increasing number of hospitals worldwide owing to the increasing incidences of diseases & disorders, increasing adoption of analyzers and rising technological advancements.

Asia Pacific: The fastest-growing region clinical chemistry analyzers market

The global clinical chemistry analyzers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centered on China and Japan. Factors such as the rising geriatric population, high burden of chronic diseases, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for cutting-edge technologies, expansion of private-sector hospitals to rural areas in various APAC countries, an increasing number of hospitals and clinics are driving the growth of the clinical chemistry analyzers market in this region.

Market Dynamics

Drivers

• Rising Geriatric Population and the Increasing Prevalence of Chronic & Lifestyle Diseases
• Growing Adoption of Point-Of-Care Testing Devices
• Increasing Demand for Laboratory Automation

Restraints

• The Requirement of High Capital Investments and a Shortage of Skilled Laboratory Technicians
• Availability of Refurbished Analyzers

Opportunities

• Increasing Government Initiatives and Funding for Preventive Care

Trends

• Multichannel Operations of Integrated Analyzers

Key Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• Abbott Laboratories (US)
• Thermo Fisher Scientific Inc. (US)
• Siemens AG (Germany)
• HORIBA Ltd. (Japan)
• Sysmex Corporation (Japan)
• HITACHI (Japan)
• EKF Diagnostics (UK)
• Ortho Clinical Diagnostics (US)
• ELITech Group (France)
• Mindray Medical International Ltd. (China)
• BIOBASE Group (China)
• SFRI Medical Diagnostics (France)
• Trivitron Healthcare Pvt. Ltd. (India)
• Randox Laboratories Ltd. (UK)
• Medica Corporation (US)
• Meril Life Sciences Pvt. Ltd. (India)
• Erba Mannheim (UK)
• Genrui Biotech Inc. (China)
• DIRUI Industrial Co. Ltd. (China)
• Teco Diagnostics (US)
• Balio Diagnostics (France)
• Snibe Co. Ltd. (China)
• AMS Alliance (Italy)

For more information about this report visit https://www.researchandmarkets.com/r/bjome7